{"product_id":"prrt-for-gastroenteropancreatic-neuroendocrine-tumors-gep-nets-a-patients-guide-to-treatment-and-sequencing","title":"PRRT for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Patient's Guide to Treatment and Sequencing","description":"\u003cp\u003ePRRT (peptide receptor radionuclide therapy) is a targeted radiation treatment that has proven highly effective for many patients with advanced, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that express somatostatin receptors. Clinical trials including NETTER-1 and NETTER-2 show that treatment with \u003cstrong\u003e177Lu-DOTATATE\u003c\/strong\u003e significantly delays tumor growth and improves symptoms, with progression-free survival improved from about 8.4 months to 22.8 months in certain grade 2 and grade 3 tumors. However, deciding when to use PRRT — early, late, or as a re-treatment — remains complex, and individual factors like tumor grade, kidney function, and disease burden play major roles. A personalized, multidisciplinary approach is essential for maximizing PRRT's benefits and minimizing risks.\u003c\/p\u003e\n\n\u003ch1\u003ePRRT for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Patient's Guide to Treatment and Sequencing\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: What Are Neuroendocrine Tumors?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#prrt-mechanism\"\u003eHow PRRT Works\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow This Review Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-findings\"\u003eKey Findings: Evidence for PRRT\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#quality-of-life\"\u003eQuality of Life and Symptom Control\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#imaging\"\u003eImaging Before and During PRRT\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#sequencing\"\u003eSequencing PRRT in Advanced GEP-NETs\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#challenges\"\u003eUnique Challenges and Safety Considerations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#trials\"\u003eOngoing Clinical Trials\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003ePRRT with 177Lu-DOTATATE is a targeted radiation treatment for advanced, well-differentiated gastroenteropancreatic neuroendocrine tumors that express somatostatin receptors.\u003c\/li\u003e\n\u003cli\u003eIn the NETTER-1 trial, median progression-free survival was 8.4 months with octreotide alone and not reached with PRRT; overall survival difference was not statistically significant, likely due to crossover.\u003c\/li\u003e\n\u003cli\u003eIn the NETTER-2 trial, first-line PRRT improved median progression-free survival to 22.8 months versus 8.5 months with high-dose octreotide in grade 2 and grade 3 SSTR-positive GEP-NETs.\u003c\/li\u003e\n\u003cli\u003ePRRT can control tumor-related symptoms and improve quality of life, but may cause kidney toxicity, blood count suppression, and rarely a hormonal crisis; kidney function and hydronephrosis must be evaluated first.\u003c\/li\u003e\n\u003cli\u003eTreatment typically involves four cycles about 8 weeks apart, with imaging 1–3 months after completion; apparent early tumor growth may be pseudo-progression from inflammation, not true progression.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: What Are Neuroendocrine Tumors?\u003c\/h2\u003e\n\u003cp\u003eNeuroendocrine neoplasms (NENs) are a highly diverse group of malignancies that can arise in several different organs throughout the body. Their clinical behavior varies significantly based on the tumor's grade and whether it secretes hormones.\u003c\/p\u003e\n\u003cp\u003eThe incidence and prevalence of NENs is rising. Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) make up about 70% of cases. They are now the second most prevalent gastrointestinal neoplasm after colon cancer.\u003c\/p\u003e\n\u003cp\u003eNENs include well-differentiated neuroendocrine tumors (WD-NETs), poorly differentiated neuroendocrine carcinomas (NECs), and mixed neuroendocrine–non-NENs. WD-NETs are further divided into three grades based on the \u003cstrong\u003eKi-67 proliferation index\u003c\/strong\u003e (a measure of how fast tumor cells are dividing) and\/or mitotic count. These grades are grade 1 (G1), grade 2 (G2), and grade 3 (G3).\u003c\/p\u003e\n\u003cp\u003eOne unique feature of NENs is their expression of \u003cstrong\u003esomatostatin receptors (SSTRs)\u003c\/strong\u003e — proteins on the cell surface that belong to a family of G-protein-coupled 7-transmembrane receptors. Most well-differentiated GEP-NETs express these receptors. By contrast, high-grade NETs and NECs can lose SSTR expression, and that loss is associated with a worse prognosis.\u003c\/p\u003e\n\u003cp\u003eThe membranous expression of SSTRs has been harnessed for \u003cstrong\u003etheranostic\u003c\/strong\u003e (therapy plus diagnostic) applications. SSTR-targeting radioligands are used both for functional imaging and for treatment. NENs are also commonly imaged with radiolabeled DOTA-conjugated peptides such as 68Ga-DOTATATE, 68Ga-DOTATOC, or 64Cu-DOTATATE using positron emission tomography\/computed tomography (PET\/CT) or PET\/magnetic resonance imaging (MRI).\u003c\/p\u003e\n\u003cp\u003eNearly 50% of NET patients have metastatic disease at the time of diagnosis. The treatment of advanced GEP-NETs is nuanced, and only limited studies establish the optimal order of therapies. A multidisciplinary approach is required.\u003c\/p\u003e\n\u003cp\u003eKey factors in creating a treatment plan include:\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTumor grade\u003c\/li\u003e\n  \u003cli\u003eTumor burden (how much disease is present)\u003c\/li\u003e\n  \u003cli\u003eTumor location\u003c\/li\u003e\n  \u003cli\u003eRate of progression\u003c\/li\u003e\n  \u003cli\u003eSymptoms\u003c\/li\u003e\n  \u003cli\u003eComorbidities (other health conditions)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eCurrent systemic therapy options include somatostatin analogs (SSAs), capecitabine\/temozolomide (oral chemotherapy), radioligand therapy with [177Lu]Lu-DOTA-TATE (177Lu-DOTATATE) for somatostatin receptor 2 (SSTR2)-positive tumors, everolimus, and tyrosine kinase inhibitors (TKIs).\u003c\/p\u003e\n\n\u003ch2 id=\"prrt-mechanism\"\u003eHow PRRT Works\u003c\/h2\u003e\n\u003cp\u003ePRRT with 177Lu-DOTATATE is a type of SSTR-targeting radionuclide therapy. It delivers cytotoxic (cell-killing) radiation directly to tumor cells.\u003c\/p\u003e\n\u003cp\u003eThe treatment causes radiation-induced DNA damage and cell death through the beta radiation-emitting properties of \u003cstrong\u003elutetium-177\u003c\/strong\u003e. Because the radiation is attached to a molecule that binds to somatostatin receptors, the radiation concentrates in tumor tissue while largely sparing normal organs.\u003c\/p\u003e\n\u003cp\u003eThe approval of PRRT in the United States in 2018 was largely driven by the publication of the \u003cstrong\u003eNETTER-1\u003c\/strong\u003e trial. That study was a phase III trial comparing 177Lu-DOTATATE plus octreotide long-acting release (LAR) 30 mg once every 4 weeks to high-dose octreotide LAR (60 mg once every 4 weeks).\u003c\/p\u003e\n\u003cp\u003eThe trial enrolled patients with advanced midgut SSTR-positive WD G1–G2 NETs (with Ki-67 ≤ 20%) whose disease had progressed on standard octreotide LAR. Patients received an activity of 200 mCi of 177Lu-DOTATATE every 8 weeks for a total of four cycles.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow This Review Was Conducted\u003c\/h2\u003e\n\u003cp\u003eThe authors of this review included significant studies that have established treatment standards for patients with well-differentiated GEP-NETs treated with PRRT.\u003c\/p\u003e\n\u003cp\u003ePapers were selected based on their impact on the literature and their relevance to the discussion. The papers were identified through expert opinion and through a literature search.\u003c\/p\u003e\n\u003cp\u003eClinical trials discussed in this review were selected based on the authors' assessment of their potential impact on the field.\u003c\/p\u003e\n\n\u003ch2 id=\"key-findings\"\u003eKey Findings: Evidence for PRRT\u003c\/h2\u003e\n\u003ch3\u003eThe NETTER-1 Trial\u003c\/h3\u003e\n\u003cp\u003eThe NETTER-1 trial met its primary endpoint of prolonging \u003cstrong\u003eprogression-free survival (PFS)\u003c\/strong\u003e — the length of time during which the tumor does not grow.\u003c\/p\u003e\n\u003cp\u003eMedian PFS was 8.4 months (95% CI: 5.8–9.1) with octreotide LAR alone. The endpoint was not reached in the PRRT arm. This difference was highly statistically significant (P \u0026lt; 0.001; hazard ratio (HR) = 0.21; 95% CI: 0.13–0.33).\u003c\/p\u003e\n\u003cp\u003eA hazard ratio of 0.21 means patients receiving PRRT had about a 79% lower risk of disease progression during the study period compared with the control group.\u003c\/p\u003e\n\u003cp\u003eOverall survival (OS) analysis at five years revealed a median OS of \u003cstrong\u003e48 months in the PRRT arm\u003c\/strong\u003e compared to \u003cstrong\u003e36.3 months in the control group\u003c\/strong\u003e. The difference in OS was not statistically significant, most likely due to a high crossover rate — meaning many patients in the control group later received PRRT, which can dilute the survival difference between groups.\u003c\/p\u003e\n\u003ch3\u003eEuropean Phase II Study Data\u003c\/h3\u003e\n\u003cp\u003eData from Europe in a single-arm phase II study of patients with GEP-NETs, bronchial NETs, and NETs of unknown primary treated with 177Lu-DOTATATE revealed:\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eMedian PFS of 29 months\u003c\/li\u003e\n  \u003cli\u003eMedian OS of 63 months\u003c\/li\u003e\n  \u003cli\u003eLongest median OS of 71 months in patients with pancreatic NETs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eInterestingly, the objective response rate (ORR — the percentage of patients whose tumors shrank measurably) in this study was \u003cstrong\u003e39%\u003c\/strong\u003e, compared to \u003cstrong\u003e18%\u003c\/strong\u003e in NETTER-1. Only 1–2% of patients achieved complete responses in both studies.\u003c\/p\u003e\n\u003cp\u003eOther prospective and retrospective studies have revealed similar response rates and survival outcomes. Although requiring further validation, newer blood-based tests known as the PRRT predictive quotient (PPQ) and NETest have been shown to predict responses to PRRT.\u003c\/p\u003e\n\u003ch3\u003eThe NETTER-2 Trial (More Recent Data)\u003c\/h3\u003e\n\u003cp\u003eMore recently, the phase III NETTER-2 trial compared 177Lu-DOTATATE plus octreotide 30 mg LAR every 4 weeks (treatment group) to high-dose octreotide 60 mg LAR every 4 weeks (control group).\u003c\/p\u003e\n\u003cp\u003eThe study enrolled patients with advanced GEP-NETs that were:\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eGrade 2 with Ki-67 ≥ 10% and ≤ 20%, or\u003c\/li\u003e\n  \u003cli\u003eGrade 3 with Ki-67 \u0026gt; 20% and ≤ 55%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAll patients had SSTR-positive disease.\u003c\/p\u003e\n\u003cp\u003eThe study revealed a median PFS of \u003cstrong\u003e8.5 months\u003c\/strong\u003e (95% CI: 7.7–13.8) in the control group versus \u003cstrong\u003e22.8 months\u003c\/strong\u003e (95% CI: 19.4–not estimated) in the 177Lu-DOTATATE group. This difference was highly significant (P \u0026lt; 0.0001; HR = 0.276; 95% CI: 0.182–0.418).\u003c\/p\u003e\n\u003cp\u003eThe objective response rate (ORR) was \u003cstrong\u003e43%\u003c\/strong\u003e in the study arm, with consistent benefit across all subgroups, including both grades and primary tumor sites.\u003c\/p\u003e\n\n\u003ch2 id=\"quality-of-life\"\u003eQuality of Life and Symptom Control\u003c\/h2\u003e\n\u003cp\u003eIn addition to radiographic (imaging) control, PRRT is also effective in controlling tumor-related symptoms.\u003c\/p\u003e\n\u003cp\u003eIn the health-related quality-of-life (QoL) analysis of NETTER-1, patients treated with 177Lu-DOTATATE had a significant improvement in time to QoL deterioration for several measures compared to patients treated with high-dose octreotide LAR. These measures included:\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eGlobal health\u003c\/li\u003e\n  \u003cli\u003ePhysical functioning\u003c\/li\u003e\n  \u003cli\u003eDiarrhea\u003c\/li\u003e\n  \u003cli\u003ePain\u003c\/li\u003e\n  \u003cli\u003eBody image\u003c\/li\u003e\n  \u003cli\u003eDisease-related worries\u003c\/li\u003e\n  \u003cli\u003eFatigue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSimilarly, Khan and colleagues reported an improvement in health-related QoL, as well as in performance status and symptoms, in patients with GEP and bronchial NETs treated with PRRT.\u003c\/p\u003e\n\u003cp\u003eOther studies have also reported an improvement in symptoms in patients with functional pancreatic NETs (tumors that secrete hormones and cause hormone-related syndromes) and refractory carcinoid symptoms in patients with small bowel NETs.\u003c\/p\u003e\n\u003cp\u003eOne important caution: there is a possibility of developing a \u003cstrong\u003eflare\u003c\/strong\u003e in functional symptoms, and rarely a hormonal crisis, during or shortly after administration of PRRT.\u003c\/p\u003e\n\n\u003ch2 id=\"imaging\"\u003eImaging Before and During PRRT\u003c\/h2\u003e\n\u003cp\u003eIn order to be eligible for 177Lu-DOTATATE PRRT, SSTR imaging must be performed beforehand.\u003c\/p\u003e\n\u003cp\u003eSSTR scintigraphy (an older imaging method) was used for inclusion criteria in NETTER-1. It has now been replaced by \u003cstrong\u003eSSTR-PET\u003c\/strong\u003e using DOTA-conjugated peptide (68Ga-DOTATATE, 68Ga-DOTATOC, or 64Cu-DOTATATE). SSTR-PET is now standard because of its substantially superior lesion detection rate.\u003c\/p\u003e\n\u003cp\u003ePositive uptake on SSTR-PET is defined as having a higher intensity of uptake or radiopharmaceutical concentration compared to normal organs. This is typically quantified using a PET measurement known as \u003cstrong\u003estandardized uptake value (SUV)\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThere are no specific SUV cutoffs to determine PRRT eligibility. Instead, a multidisciplinary discussion with the nuclear medicine team is necessary to determine whether there is sufficient positive uptake for the patient to derive meaningful benefit from PRRT. This discussion must also consider other potential treatment options.\u003c\/p\u003e\n\u003cp\u003eThere are retrospective studies suggesting that pretreatment SSTR-PET uptake can serve as both:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eA predictive marker for response to PRRT\u003c\/li\u003e\n  \u003cli\u003eA prognostic marker (a predictor of overall outcome) for NET patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThese findings have not yet been validated prospectively.\u003c\/p\u003e\n\u003cp\u003eAs mentioned earlier, high-grade NENs can either lose SSTR expression or have heterogeneous SSTR expression on imaging. Very rarely, well-differentiated low-grade NETs can also have absence of SSTR expression, resulting in negative SSTR imaging.\u003c\/p\u003e\n\u003cp\u003eThe increased proliferation rate and aggressive biology of high-grade NENs present an opportunity to use \u003cstrong\u003e18F-FDG PET\/CT\u003c\/strong\u003e for accurate staging when uptake on SSTR imaging is either negative or heterogeneous. FDG PET measures glucose metabolism, which is typically higher in more aggressive tumors.\u003c\/p\u003e\n\u003cp\u003eHigh uptake on 18F-FDG PET\/CT is associated with:\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eLower objective response rate (ORR) after PRRT\u003c\/li\u003e\n  \u003cli\u003eShorter progression-free survival (PFS)\u003c\/li\u003e\n  \u003cli\u003eShorter overall survival (OS)\u003c\/li\u003e\n  \u003cli\u003ePoor prognosis overall\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhile there is a lack of consensus on whether 18F-FDG PET should be obtained at baseline for patients with high-grade NENs, many NET oncologists obtain both SSTR and FDG PET scans at diagnosis.\u003c\/p\u003e\n\u003cp\u003eChan and colleagues proposed the \u003cstrong\u003eNETPET grading system\u003c\/strong\u003e, which incorporates the degree of uptake on both SSTR and FDG PET\/CT performed within a month of each other. In their study, the highest of five grades — representing FDG uptake greater than SSTR uptake — demonstrated the lowest overall survival. This finding supports its use as a potential prognostic imaging biomarker.\u003c\/p\u003e\n\u003cp\u003eTypically, diagnostic imaging for response assessment is performed \u003cstrong\u003e1–3 months after completion of four doses of PRRT\u003c\/strong\u003e. Although not currently standard, there may be a role for individualized dosimetric assessments using post-177Lu-DOTATATE scintigraphy with SPECT\/CT for treatment planning. This approach is being studied in several ongoing clinical trials.\u003c\/p\u003e\n\u003cp\u003eOutside of dosimetric assessments, imaging between cycles is done every 3–4 months at some centers, particularly if there is concern for clinical progression.\u003c\/p\u003e\n\u003cp\u003ePatients should know that a flare in functional symptoms, and rarely a hormonal crisis, can occur during or shortly after PRRT administration. A transient rise in tumor markers and liver function enzymes is also sometimes seen. This needs to be considered when deciding whether to obtain mid-treatment imaging.\u003c\/p\u003e\n\u003cp\u003eThere are currently no specific guidelines on whether to use anatomical imaging or SSTR functional imaging for response assessment. In most cases, cross-sectional imaging with contrast-enhanced CT, or MRI for liver-predominant disease, is sufficient.\u003c\/p\u003e\n\u003cp\u003eIt is important to understand the possibility of \u003cstrong\u003epseudo-progression\u003c\/strong\u003e — an apparent worsening on anatomical imaging during or shortly after completion of PRRT. This occurs due to a transient increase in tumor size, most likely from radiation-induced inflammation and edema. Functional imaging can help distinguish pseudo-progression from true progression. The subsequent timing and choice of imaging depend on tumor biology, burden of disease, and response to PRRT.\u003c\/p\u003e\n\n\u003ch2 id=\"sequencing\"\u003eSequencing PRRT in Advanced GEP-NETs\u003c\/h2\u003e\n\u003cp\u003eOf the treatment options for advanced GEP-NETs, the timing and sequencing of PRRT should be evaluated based on several factors:\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTumor biology\u003c\/li\u003e\n  \u003cli\u003eDisease burden\u003c\/li\u003e\n  \u003cli\u003ePrimary tumor site as well as metastatic sites\u003c\/li\u003e\n  \u003cli\u003eThe need for tumor response\u003c\/li\u003e\n  \u003cli\u003eComorbidities\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eUntil the NETTER-2 trial, most studies on patients treated with 177Lu-DOTATATE involved patients whose disease had progressed after first-line SSA therapy. NETTER-2 established a role for PRRT in the \u003cstrong\u003efrontline setting\u003c\/strong\u003e for patients with advanced grade 2 or 3 disease.\u003c\/p\u003e\n\u003cp\u003eFor most patients with advanced low-grade GEP-NETs, first-line treatment with SSA alone is effective in providing long-term symptom and disease control. Surgical debulking and liver-directed therapy should also be considered and discussed in a multidisciplinary setting.\u003c\/p\u003e\n\u003ch3\u003eSecond-Line Treatment of Low-Grade GEP-NETs\u003c\/h3\u003e\n\u003cp\u003eFor second-line treatment of low-grade GEP-NETs, there is not one optimal sequence. Each patient's treatment should be individualized and discussed in a multidisciplinary setting.\u003c\/p\u003e\n\u003cp\u003eTreatment options include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eEverolimus\u003c\/li\u003e\n  \u003cli\u003eCapecitabine\/temozolomide\u003c\/li\u003e\n  \u003cli\u003eTyrosine kinase inhibitors (TKIs): sunitinib for pancreatic NETs and cabozantinib for midgut and pancreatic NETs\u003c\/li\u003e\n  \u003cli\u003e177Lu-DOTATATE\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor patients with high-volume or symptomatic low-grade GEP-NETs, incorporating 177Lu-DOTATATE over everolimus and TKIs is reasonable.\u003c\/p\u003e\n\u003cp\u003eFor patients where accelerated cytoreduction (rapid tumor shrinkage) is required, sequencing capecitabine\/temozolomide over other treatment options should be considered.\u003c\/p\u003e\n\u003cp\u003eFor patients with low-grade midgut NETs, responses with capecitabine\/temozolomide are not as impressive. Sequencing 177Lu-DOTATATE earlier in treatment for symptomatic patients is reasonable.\u003c\/p\u003e\n\u003ch3\u003ePRRT After Other Therapies and in the Frontline Setting\u003c\/h3\u003e\n\u003cp\u003eData suggest that sequencing 177Lu-based PRRT after everolimus and after cytotoxic chemotherapy is safe and feasible in patients with GEP-NETs.\u003c\/p\u003e\n\u003cp\u003eThe NETTER-2 phase III trial showed an improvement in median PFS of about 14 months with first-line 177Lu-DOTATATE plus octreotide 30 mg LAR every 4 weeks, compared to high-dose octreotide 60 mg LAR every 4 weeks. This benefit was seen in patients with grade 2 (Ki-67 ≥ 10% and ≤ 20%) and grade 3 (Ki-67 \u0026gt; 20% and ≤ 55%) SSTR-positive advanced GEP-NETs.\u003c\/p\u003e\n\u003cp\u003eHigh-grade NETs include a wide range of Ki-67 values and can have significantly varied biology, ranging from relatively indolent (slow-growing) disease to rapidly progressive tumors. The impressive improvement in median PFS from NETTER-2 should be carefully assessed together with each individual patient's characteristics.\u003c\/p\u003e\n\u003cp\u003eFirst-line PRRT should be considered in this patient population. However, it may not be indicated in:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eAsymptomatic patients\u003c\/li\u003e\n  \u003cli\u003ePatients with low symptom burden\u003c\/li\u003e\n  \u003cli\u003ePatients with low disease burden\u003c\/li\u003e\n  \u003cli\u003ePatients with slower growth rates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor patients with rapidly progressive, high-volume disease, or patients in \u003cstrong\u003evisceral crisis\u003c\/strong\u003e (a life-threatening situation caused by rapid tumor growth or hormone secretion), cytotoxic chemotherapy should be considered over PRRT.\u003c\/p\u003e\n\n\u003ch2 id=\"challenges\"\u003eUnique Challenges and Safety Considerations\u003c\/h2\u003e\n\u003cp\u003eWhen considering PRRT, it is critical to carefully individualize the treatment plan to each NET patient's unique needs. This includes consideration of tumor biology, grade, prior treatments, and the known tempo of the patient's disease course.\u003c\/p\u003e\n\u003cp\u003ePRRT was approved based on the NETTER-1 study. That study selected healthier patients with robust organ function. The exclusion criteria for NETTER-1 included patients with creatinine clearance of less than 50 mL\/min, as well as low albumin levels. The study selected patients who would be less likely to experience known toxicities of radioligand therapy, with particular emphasis on patients with normal kidney function and normal liver function.\u003c\/p\u003e\n\u003cp\u003eIn the real world, however, exceptions have to be made. Patients who fall outside the specific parameters in NETTER-1 can still benefit from PRRT. Understanding the impact of PRRT in unique situations — including decreased organ function, high disease burden, prior cytotoxic treatments, and prior radiation — can help oncologists tailor treatment to each individual NET patient.\u003c\/p\u003e\n\u003ch3\u003ePRRT in Patients with Chronic Kidney Disease (CKD)\u003c\/h3\u003e\n\u003cp\u003eConcern for renal (kidney) toxicity from PRRT is based on the risk of radiation damage to the kidneys. With renal protective amino acid infusions, the risk of acute kidney toxicity in patients with creatinine clearance greater than 50 mL\/min is low.\u003c\/p\u003e\n\u003cp\u003eAn important question remains for patients with creatinine clearance below 50 mL\/min. There is concern that, with decreasing renal function, increased radioligand peptide is absorbed in the proximal tubule of the kidney, raising the risk of radiation-induced nephrotoxicity (kidney damage).\u003c\/p\u003e\n\u003cp\u003eHowever, a subgroup analysis of NETTER-1 provided reassuring data. In the 177Lu-DOTATATE arm, there were:\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e11 patients with mild baseline renal dysfunction (creatinine clearance 50–60 mL\/min)\u003c\/li\u003e\n  \u003cli\u003e13 patients with moderate dysfunction (creatinine clearance below 50 mL\/min)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThose patients with mild or moderate renal dysfunction had no increased risk of renal toxicity or decompensation of renal function over time.\u003c\/p\u003e\n\u003cp\u003eAnother prospective study of 177Lu-DOTATATE in 51 patients found that the median creatinine for the entire group increased from baseline one year after treatment. Seventeen patients had a more severe reduction in creatinine clearance of 20% or greater. Patients with other risk factors for chronic kidney disease, including hypertension and diabetes, were at highest risk of renal decompensation with PRRT treatment. The authors described one patient in the group with a more severe decline in renal function after PRRT that was associated with hydronephrosis (kidney swelling caused by urine backup).\u003c\/p\u003e\n\u003cp\u003eKey safety points for special situations based on the review:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChronic kidney disease:\u003c\/strong\u003e PRRT appears safe in most patients with creatinine clearance above 30 mL\/min. Consider dose reduction and additional hydration. Hydronephrosis must be corrected before PRRT.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCytopenia (low blood counts) or pre-existing CHIP (clonal hematopoiesis of indeterminate potential):\u003c\/strong\u003e Hematologic toxicity is a potential risk with PRRT. Consider dose reduction and alternatives in high-risk patients. This is an ongoing area of active research.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePeritoneal metastatic disease (disease spread in the abdominal lining):\u003c\/strong\u003e PRRT is well tolerated even with peritoneal disease. For those at highest risk, consider prophylactic steroids after treatment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHigh-volume liver metastasis:\u003c\/strong\u003e PRRT is well tolerated in many patients with a high burden of metastatic liver disease. Liver function is a more important parameter of the risk of hepatic toxicity than tumor volume or burden in the liver.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSequencing with prior Y90 radioembolization:\u003c\/strong\u003e Patients with a high volume of prior Y90 radioembolization treatment may be at a higher risk of hepatotoxicity (liver damage) after PRRT.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRe-treatment with PRRT:\u003c\/strong\u003e Salvage PRRT with two additional cycles can be done safely and effectively in patients who have already received an initial four cycles of PRRT.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eHydronephrosis and Kidney Risk\u003c\/h3\u003e\n\u003cp\u003ePatients with NENs, particularly midgut NENs, are at an increased risk of hydronephrosis. This can be related to metastatic tumor deposits or to mesenteric fibrosis (scarring in the tissue that supports the intestines).\u003c\/p\u003e\n\u003cp\u003eThe risk of renal toxicity in patients with hydronephrosis is high. This is because radioligand particles can pool in the kidney, increasing radiation exposure. Patients with hydronephrosis require close collaboration with urology and correction of the hydronephrosis before PRRT, in order to prevent radiation exposure and permanent renal toxicity.\u003c\/p\u003e\n\u003cp\u003eRetrospective studies have also evaluated the risk of renal decompensation in patients receiving PRRT. One single-center retrospective analysis identified 33 patients with an estimated glomerular filtration rate (eGFR) of less than 60 mL\/min\/1.73 m². Of these, 26 had more severe kidney disease with a GFR of 45–60 mL\/min\/1.73 m², and 7 had GFR levels below that range.\u003c\/p\u003e\n\n\u003ch2 id=\"trials\"\u003eOngoing Clinical Trials\u003c\/h2\u003e\n\u003cp\u003eSeveral ongoing clinical trials are exploring ways to improve PRRT and better define its place in treatment. These are relevant to patients discussing PRRT with their care team.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDosimetry-based PRRT:\u003c\/strong\u003e Trials such as DOBATOC (NCT04917484) and LUMOD-ID (NCT06395402) compare standard PRRT dosing to individualized doses based on patient-specific dosimetry measurements.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePRRT combined with chemotherapy:\u003c\/strong\u003e An Alliance-led randomized phase II trial (NCT05247905) is comparing capecitabine and temozolomide combined with 177Lu-DOTATATE for advanced pancreatic NETs.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNewer radiopharmaceuticals:\u003c\/strong\u003e The COMPOSE trial (NCT04919226) is testing 177Lu-EDOTREOTIDE versus best standard of care in grade 2\/3 GEP-NETs. The COMPETE trial (NCT03049189) is comparing 177Lu-EDOTREOTIDE PRRT to everolimus in well-differentiated GEP-NETs.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNeoadjuvant PRRT:\u003c\/strong\u003e A phase I trial (NCT04609592) is studying PRRT before cytoreductive surgery in patients with grade 1 or 2 SSTR-positive GEP-NETs.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePRRT combined with PARP inhibitors:\u003c\/strong\u003e The PRRT-PARPis trial (NCT05870423) tests olaparib with PRRT after progression on initial PRRT. Another trial (NCT05053854) tests talazoparib in combination with 177Lu-DOTA-Octreotate PRRT.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePRRT combined with other drugs:\u003c\/strong\u003e A phase II trial (NCT05724108) is testing the drug triapine with 177Lu-DOTATATE. An Imperial College London trial (NCT05178693) studies ASTX727 in combination with Lutathera.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNew delivery forms:\u003c\/strong\u003e A phase I trial (NCT05475210) studies 177Lu-DOTA-EB-TATE in advanced GEP-NETs, as does the ALPHAMEDIX02 trial (NCT05153772) with a targeted alpha-emitter therapy (212Pb-DOTAMTATE) in PRRT-naïve and previously treated NET patients.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRetreatment and next steps:\u003c\/strong\u003e The NETRETREAT trial (NCT05773274) compares retreatment with 177Lu-DOTATATE to everolimus in metastatic unresectable midgut NETs. The ACTION-1 trial (NCT05477576) studies RYZ101 compared with standard of care in patients who progressed after 177Lu-SSA therapy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNETTER-3\u003c\/strong\u003e (NCT06784752) is a phase III randomized trial evaluating PRRT versus standard of care in patients with grade 1 and grade 2 advanced GEP-NETs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications\u003c\/h2\u003e\n\u003cp\u003ePRRT has proven effective for patients with advanced, somatostatin receptor-positive NETs. This is especially true for patients with inoperable tumors or those whose disease is progressing after other therapies.\u003c\/p\u003e\n\u003cp\u003ePRRT plays a vital role in the overall management of GEP-NETs. However, its sequencing with other treatments remains complex. Current evidence supports using PRRT both early and late in the treatment journey, depending on individual patient factors.\u003c\/p\u003e\n\u003cp\u003eThe NETTER-2 results are practice-changing for grade 2 and grade 3 disease. Select patients with higher Ki-67 levels now have an option for PRRT as their first treatment. At the same time, not every patient needs early PRRT. Patients with slow-growing, low-burden, low-symptom disease may do well with an SSA first.\u003c\/p\u003e\n\u003cp\u003eFor patients with high-volume or symptomatic low-grade tumors, PRRT appears to be a reasonable choice over everolimus and TKIs. If rapid tumor shrinkage is needed, chemotherapy may be preferred. In small bowel NETs, where chemotherapy responses are less impressive, earlier PRRT for symptom control is a sensible option.\u003c\/p\u003e\n\u003cp\u003eThe safety data support careful evaluation of kidney function, prior liver-directed therapy, and blood counts before starting PRRT. Most patients with mild to moderate kidney impairment can be treated safely with appropriate precautions.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations\u003c\/h2\u003e\n\u003cp\u003eThis article is a review, not a single clinical trial. The authors selected studies based on expert opinion and perceived impact, which carries some risk of selection bias.\u003c\/p\u003e\n\u003cp\u003eSeveral important questions remain unanswered. The overall survival benefit in NETTER-1 did not reach statistical significance, likely because many patients in the control group crossed over to receive PRRT. This crossover makes it harder to prove a survival advantage from PRRT alone.\u003c\/p\u003e\n\u003cp\u003eThe role of SSTR-PET uptake as a predictive or prognostic marker has not been validated prospectively. There are no standard SUV cutoffs to determine eligibility.\u003c\/p\u003e\n\u003cp\u003eThe optimal sequencing of PRRT with other treatments is not established by large, randomized, head-to-head trials. Much of the guidance in second-line treatment of low-grade tumors is based on smaller studies and expert consensus rather than definitive phase III data.\u003c\/p\u003e\n\u003cp\u003eAdditionally, biomarkers such as the PPQ and NETest show promise for predicting response to PRRT, but they still require further validation before becoming routine clinical tools.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\u003cp\u003ePatients with advanced GEP-NETs should be treated at centers with a multidisciplinary NET team. This team typically includes medical oncologists, nuclear medicine specialists, surgeons, radiologists, and pathologists.\u003c\/p\u003e\n\u003cp\u003eAsk your care team the following questions when discussing PRRT:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eDid my tumor test positive on SSTR-PET imaging, and is the uptake high enough to expect a meaningful benefit?\u003c\/li\u003e\n  \u003cli\u003eWhat is my tumor grade and Ki-67 index? Does this suggest I might benefit from PRRT early in my treatment?\u003c\/li\u003e\n  \u003cli\u003eWhat is my current kidney function, and do I need any additional evaluation such as a renal scan or correction of hydronephrosis before starting PRRT?\u003c\/li\u003e\n  \u003cli\u003eWhat other treatments might be appropriate before or after PRRT, based on my specific tumor type and symptoms?\u003c\/li\u003e\n  \u003cli\u003eIf my tumor is growing rapidly or causing severe symptoms, is chemotherapy a better first option than PRRT?\u003c\/li\u003e\n  \u003cli\u003eIs there a clinical trial available that might improve my treatment outcomes?\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eIf PRRT is recommended, patients typically receive four cycles given approximately 8 weeks apart. Each treatment is followed by radiation safety precautions for a period of time, which your team will explain.\u003c\/p\u003e\n\u003cp\u003eMonitoring after PRRT generally includes imaging at 1–3 months after treatment completion, with follow-up scans every 3–6 months depending on tumor biology and clinical status.\u003c\/p\u003e\n\u003cp\u003eRemember that apparent tumor growth on early scans after PRRT may be pseudo-progression from inflammation rather than true resistance. Ask your doctor whether functional imaging could help clarify the picture.\u003c\/p\u003e\n\u003cp\u003ePatients with kidney disease, prior liver radiation, blood count abnormalities, or prior chemotherapy should discuss whether dose adjustments or additional protective measures are warranted. Surgery to correct hydronephrosis should be completed before PRRT when needed.\u003c\/p\u003e\n\u003cp\u003eFinally, because the field is evolving rapidly, patients are encouraged to seek updated information and consider clinical trials exploring better PRRT delivery, combination therapies, and newer agents.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is PRRT and how does it work?\u003c\/h3\u003e\n\u003cp\u003ePRRT (peptide receptor radionuclide therapy) is a targeted radiation treatment. It uses a molecule that binds to somatostatin receptors on tumor cells, carrying the radioactive isotope lutetium-177. This delivers cell-killing beta radiation directly to the tumor, causing DNA damage and cell death, while largely sparing normal organs. It is used for advanced, well-differentiated gastroenteropancreatic neuroendocrine tumors that express somatostatin receptors.\u003c\/p\u003e\n\u003ch3\u003eAm I eligible for PRRT?\u003c\/h3\u003e\n\u003cp\u003eEligibility requires a positive somatostatin receptor PET scan showing sufficient uptake. There are no specific SUV cutoffs; a multidisciplinary team decides if uptake is high enough for meaningful benefit. PRRT is approved for SSTR-positive advanced GEP-NETs. Patients with poor kidney function (creatinine clearance below 50 mL\/min) were excluded from the NETTER-1 trial, but real-world exceptions are made. Your tumor grade, prior treatments, and overall health are also considered.\u003c\/p\u003e\n\u003ch3\u003eWhat does the progression-free survival number mean?\u003c\/h3\u003e\n\u003cp\u003eProgression-free survival (PFS) is the time during which the tumor does not grow. In the NETTER-1 trial, median PFS was 8.4 months with octreotide alone, while it was not reached in the PRRT arm. In NETTER-2, median PFS was 8.5 months in the control group versus 22.8 months with PRRT. These numbers describe group averages, not individual outcomes.\u003c\/p\u003e\n\u003ch3\u003eWhat are the main risks or side effects of PRRT?\u003c\/h3\u003e\n\u003cp\u003ePRRT can cause kidney damage, especially if kidney function is already reduced or if hydronephrosis is present. Blood count suppression (cytopenia) is possible. A flare in functional symptoms, and rarely a hormonal crisis, can occur during or shortly after treatment. Pseudo-progression—apparent tumor growth on scans due to inflammation—may happen. Prior Y90 radioembolization may increase liver toxicity risk. Your team will monitor and take precautions.\u003c\/p\u003e\n\u003ch3\u003eHow is PRRT given and what happens after?\u003c\/h3\u003e\n\u003cp\u003ePRRT is usually given as four cycles, approximately 8 weeks apart. Each treatment is followed by radiation safety precautions for a period of time, which your team will explain. After completing treatment, imaging is typically done 1–3 months later, with follow-up scans every 3–6 months depending on tumor biology and clinical status. A transient rise in tumor markers and liver enzymes can sometimes be seen.\u003c\/p\u003e\n\u003ch3\u003eCan PRRT be used as a first treatment?\u003c\/h3\u003e\n\u003cp\u003eYes, for some patients. The NETTER-2 trial showed that first-line PRRT plus octreotide improved median progression-free survival by about 14 months compared to high-dose octreotide in patients with grade 2 (Ki-67 10–20%) or grade 3 (Ki-67 \u0026gt;20–55%) SSTR-positive advanced GEP-NETs. However, first-line PRRT may not be indicated for asymptomatic patients, those with low symptom burden, low disease burden, or slower growth rates.\u003c\/p\u003e\n\u003ch3\u003eWhat should I ask my care team about PRRT?\u003c\/h3\u003e\n\u003cp\u003eAsk: Did my tumor test positive on SSTR-PET, and is uptake high enough? What is my tumor grade and Ki-67? What is my kidney function, and do I need a renal scan or hydronephrosis correction? What other treatments might be appropriate before or after PRRT? If my tumor is growing rapidly or causing severe symptoms, is chemotherapy a better first option? Is there a clinical trial available?\u003c\/p\u003e\n\u003ch3\u003eWhen should a patient with advanced GEP-NETs considering PRRT seek a second opinion?\u003c\/h3\u003e\n\u003cp\u003eSeek a second opinion when the timing or sequence of PRRT is unclear. Sequencing PRRT with somatostatin analogs, everolimus, tyrosine kinase inhibitors, or chemotherapy is complex, and no large randomized trials establish one optimal order. A second review can help confirm tumor grade and Ki-67, assess SSTR-PET uptake, and evaluate kidney function, prior liver-directed therapy, and blood counts before treatment. Patients with high-volume or symptomatic low-grade tumors, or grade 2 and 3 disease, may benefit from multidisciplinary input on whether PRRT should come earlier or later. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Corbett V, Gupta G, Chauhan A.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Endocrine-Related Cancer (2026) 33 e250495. Published by Bioscientifica Ltd. Article received 26 November 2025, accepted 26 February 2026, available online 2 March 2026, version of record published 23 March 2026.\u003c\/p\u003e\n\u003cp\u003eCorrespondence: Aman Chauhan, MD, Department of Hematology and Oncology, Helen Diller Family Comprehensive Cancer Center, UCSF: aman.chauhan@ucsf.edu\u003c\/p\u003e\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e This article is licensed under a Creative Commons Attribution 4.0 International License.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47738950123676,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/de\/products\/prrt-for-gastroenteropancreatic-neuroendocrine-tumors-gep-nets-a-patients-guide-to-treatment-and-sequencing","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}